Most Popular
-
1
Dongduk Women’s University halts coeducation talks
-
2
Defense ministry denies special treatment for BTS’ V amid phone use allegations
-
3
Russia sent 'anti-air' missiles to Pyongyang, Yoon's aide says
-
4
OpenAI in talks with Samsung to power AI features, report says
-
5
Two jailed for forcing disabled teens into prostitution
-
6
South Korean military plans to launch new division for future warfare
-
7
Trump picks ex-N. Korea policy official as his principal deputy national security adviser
-
8
Gold bars and cash bundles; authorities confiscate millions from tax dodgers
-
9
Kia EV9 GT marks world debut at LA Motor Show
-
10
Teen smoking, drinking decline, while mental health, dietary habits worsen
[THE INVESTOR] Samsung BioLogics is expected to raise up to 2.25 trillion won (US$2.04 billion) through its planned initial public offering next month, which will be the third-largest stock sale in the country’s history.
According to a securities registration statement of Samsung Group’s biopharmaceutical contract manufacturing arm on Oct. 4, it will seek to sell some 16.54 million shares at 113,000 won to 136,000 won.
If the company prices its IPO at the top end of its proposed range, it could raise 2.249 trillion won.
According to a securities registration statement of Samsung Group’s biopharmaceutical contract manufacturing arm on Oct. 4, it will seek to sell some 16.54 million shares at 113,000 won to 136,000 won.
If the company prices its IPO at the top end of its proposed range, it could raise 2.249 trillion won.
